Beijing Hotgen Biotech Co Ltd
SSE:688068
Beijing Hotgen Biotech Co Ltd
SSE:688068
Price:
125.4
CNY
-0.67%
Market Closed
Market Cap:
¥11.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
CN |
|
ZongTai Real Estate Development Co Ltd
TWSE:3056
|
TW |
|
2Crsi SA
PAR:AL2SI
|
FR |
|
C
|
China NT Pharma Group Company Ltd
HKEX:1011
|
CN |
|
M&L Holdings Group Ltd
HKEX:8152
|
HK |
|
China E-Wallet Payment Group Ltd
HKEX:802
|
MY |
|
Hindustan Fluoro Carbons Ltd
BSE:524013
|
IN |
Income Statement
Earnings Waterfall
Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co Ltd
Income Statement
Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co Ltd
Currency: CNY
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
199
N/A
|
203
+2%
|
210
+4%
|
212
+1%
|
206
-3%
|
218
+6%
|
514
+135%
|
1 703
+232%
|
4 023
+136%
|
4 164
+3%
|
5 369
+29%
|
5 506
+3%
|
3 815
-31%
|
4 583
+20%
|
3 557
-22%
|
2 395
-33%
|
1 818
-24%
|
954
-48%
|
548
-43%
|
454
-17%
|
483
+6%
|
520
+8%
|
511
-2%
|
488
-4%
|
466
-5%
|
434
-7%
|
|
| Gross Profit | |||||||||||||||||||||||||||
| Cost of Revenue |
(56)
|
(57)
|
(57)
|
(57)
|
(58)
|
(66)
|
(190)
|
(597)
|
(1 486)
|
(1 610)
|
(2 254)
|
(2 271)
|
(1 742)
|
(2 046)
|
(1 766)
|
(1 209)
|
(876)
|
(472)
|
(212)
|
(224)
|
(259)
|
(276)
|
(257)
|
(236)
|
(199)
|
(190)
|
|
| Gross Profit |
143
N/A
|
146
+2%
|
154
+5%
|
155
+1%
|
149
-4%
|
152
+3%
|
324
+112%
|
1 106
+242%
|
2 537
+129%
|
2 553
+1%
|
3 116
+22%
|
3 235
+4%
|
2 073
-36%
|
2 537
+22%
|
1 790
-29%
|
1 186
-34%
|
942
-21%
|
483
-49%
|
336
-30%
|
230
-31%
|
224
-3%
|
245
+9%
|
254
+4%
|
252
0%
|
267
+6%
|
245
-8%
|
|
| Operating Income | |||||||||||||||||||||||||||
| Operating Expenses |
(92)
|
(97)
|
(120)
|
(118)
|
(129)
|
(136)
|
(205)
|
(279)
|
(695)
|
(713)
|
(530)
|
(648)
|
(261)
|
(421)
|
(679)
|
(800)
|
(782)
|
(650)
|
(301)
|
(302)
|
(354)
|
(359)
|
(406)
|
(487)
|
(492)
|
(505)
|
|
| Selling, General & Administrative |
(84)
|
(87)
|
(82)
|
(98)
|
(107)
|
(113)
|
(140)
|
(230)
|
(347)
|
(379)
|
(374)
|
(416)
|
(325)
|
(423)
|
(448)
|
(459)
|
(448)
|
(350)
|
(214)
|
(249)
|
(278)
|
(281)
|
(230)
|
(303)
|
(306)
|
(325)
|
|
| Research & Development |
(22)
|
(25)
|
(28)
|
(31)
|
(33)
|
(34)
|
(45)
|
(57)
|
(91)
|
(104)
|
(129)
|
(160)
|
(153)
|
(187)
|
(185)
|
(179)
|
(177)
|
(152)
|
(126)
|
(120)
|
(113)
|
(109)
|
(100)
|
(111)
|
(111)
|
(104)
|
|
| Depreciation & Amortization |
0
|
0
|
(19)
|
0
|
0
|
0
|
(26)
|
0
|
0
|
0
|
(41)
|
0
|
0
|
0
|
(60)
|
0
|
0
|
0
|
(49)
|
0
|
0
|
0
|
(85)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
15
|
15
|
8
|
10
|
11
|
11
|
6
|
7
|
(257)
|
(230)
|
14
|
(72)
|
217
|
190
|
13
|
(162)
|
(157)
|
(149)
|
88
|
67
|
37
|
31
|
10
|
(72)
|
(74)
|
(77)
|
|
| Operating Income |
51
N/A
|
50
-2%
|
34
-32%
|
37
+9%
|
20
-46%
|
17
-16%
|
118
+609%
|
826
+598%
|
1 843
+123%
|
1 840
0%
|
2 585
+40%
|
2 587
+0%
|
1 812
-30%
|
2 116
+17%
|
1 111
-47%
|
386
-65%
|
160
-59%
|
(168)
N/A
|
35
N/A
|
(72)
N/A
|
(129)
-80%
|
(115)
+11%
|
(152)
-33%
|
(234)
-54%
|
(224)
+4%
|
(260)
-16%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||
| Interest Income Expense |
1
|
0
|
4
|
4
|
7
|
8
|
10
|
9
|
11
|
24
|
21
|
38
|
38
|
41
|
45
|
40
|
38
|
8
|
16
|
25
|
19
|
47
|
23
|
23
|
(9)
|
4
|
|
| Non-Reccuring Items |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(23)
|
(14)
|
(15)
|
(14)
|
(71)
|
(0)
|
(0)
|
(0)
|
(34)
|
1
|
(0)
|
1
|
(57)
|
(3)
|
(1)
|
(3)
|
|
| Total Other Income |
(0)
|
(1)
|
1
|
0
|
0
|
1
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(6)
|
(8)
|
(7)
|
(10)
|
(12)
|
(10)
|
(11)
|
(2)
|
(5)
|
(5)
|
(3)
|
(1)
|
(2)
|
(2)
|
(3)
|
|
| Pre-Tax Income |
52
N/A
|
50
-4%
|
38
-23%
|
41
+7%
|
27
-33%
|
26
-6%
|
127
+396%
|
835
+555%
|
1 852
+122%
|
1 862
+1%
|
2 582
+39%
|
2 605
+1%
|
1 828
-30%
|
2 136
+17%
|
1 075
-50%
|
414
-62%
|
188
-55%
|
(171)
N/A
|
15
N/A
|
(51)
N/A
|
(116)
-128%
|
(69)
+40%
|
(188)
-170%
|
(217)
-16%
|
(236)
-9%
|
(262)
-11%
|
|
| Net Income | |||||||||||||||||||||||||||
| Tax Provision |
(7)
|
(7)
|
(4)
|
(5)
|
(4)
|
(2)
|
(16)
|
(122)
|
(281)
|
(269)
|
(379)
|
(388)
|
(259)
|
(313)
|
(150)
|
(48)
|
(15)
|
38
|
2
|
13
|
9
|
(5)
|
(8)
|
(7)
|
1
|
(2)
|
|
| Income from Continuing Operations |
45
|
43
|
34
|
36
|
23
|
24
|
111
|
713
|
1 571
|
1 593
|
2 202
|
2 216
|
1 570
|
1 823
|
925
|
366
|
173
|
(133)
|
17
|
(38)
|
(107)
|
(75)
|
(196)
|
(224)
|
(235)
|
(264)
|
|
| Income to Minority Interest |
0
|
(0)
|
0
|
1
|
1
|
2
|
1
|
0
|
(9)
|
(10)
|
(17)
|
(26)
|
(22)
|
(12)
|
20
|
32
|
41
|
31
|
12
|
11
|
6
|
7
|
5
|
4
|
4
|
4
|
|
| Net Income (Common) |
45
N/A
|
43
-5%
|
34
-21%
|
36
+7%
|
24
-33%
|
26
+5%
|
112
+336%
|
713
+536%
|
1 563
+119%
|
1 583
+1%
|
2 186
+38%
|
2 190
+0%
|
1 548
-29%
|
1 811
+17%
|
945
-48%
|
398
-58%
|
215
-46%
|
(102)
N/A
|
29
N/A
|
(26)
N/A
|
(101)
-281%
|
(68)
+33%
|
(191)
-182%
|
(220)
-15%
|
(232)
-5%
|
(259)
-12%
|
|
| EPS (Diluted) |
0.96
N/A
|
0.96
N/A
|
0.67
-30%
|
0.7
+4%
|
0.33
-53%
|
0.42
+27%
|
1.8
+329%
|
11.46
+537%
|
16.97
+48%
|
17.2
+1%
|
23.75
+38%
|
23.79
+0%
|
16.81
-29%
|
19.67
+17%
|
10.26
-48%
|
4.45
-57%
|
2.4
-46%
|
-1.15
N/A
|
0.32
N/A
|
-0.31
N/A
|
-1.05
-239%
|
-0.73
+30%
|
-2.12
-190%
|
-2.37
-12%
|
-2.62
-11%
|
-3.04
-16%
|
|
Switch to:
Switch to:
See Also
Discover More
